➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Mallinckrodt
McKesson
Colorcon
Dow

Last Updated: March 2, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01247259 Efficacy of Sublingual Immunotherapy in Polysensitized Allergic Rhinitis Patients Completed Seoul National University Hospital N/A 2007-11-01 Recently, interest has increased in sublingual immunotherapy (SLIT) for treating allergic rhinitis. It is often suggested that polysensitized patients might not benefit from specific immunotherapy as much as monosensitized patients, although further research on this subject is needed. This study compared the efficacy of SLIT with standardized house dust mite extract in mono- and polysensitized allergic rhinitis patients. Patients who were sensitized to house dust mites and treated with SLIT for house dust mites for at least 1 year between November 2007 and March 2010 were included. The mono-allergen sensitized group (Mgr) was defined as the patients who were sensitized to Dermatophagoides pteronyssinus (Dp) or D. farinae (Df; n = 70). The poly-allergen sensitized group (Pgr) was defined as the patients who were simultaneously sensitized to house dust mites and other allergens (n = 64). A standardized extract of house dust mites was used for immunotherapy. Anti-allergic medication and the total nasal symptom score (TNSS), including rhinorrhea, sneezing, nasal obstruction, and itchy nose, were evaluated before and 1 year after SLIT. This study enrolled 134 patients. The TNSS improved significantly after SLIT in both groups, while the change in the TNSS did not differ significantly between the groups. The anti-allergic medication scores also decreased significantly in both groups, but there was no significant difference between the groups. In polysensitized allergic rhinitis patients, SLIT for Dp/Df gave comparable improvements in both nasal symptoms and rescue medication scores to those in monosensitized patients, regardless of other positive allergens. SLIT for Dp/Df might be considered in polysensitized allergic rhinitis patients.
NCT01291381 Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children Completed Beijing Tongren Hospital N/A 2009-02-01 While allergen specific immunotherapy (SIT) is highly effective for allergic diseases in children, the underlying immunological mechanisms are unclear. Regulatory T (Treg) cells may be crucial in induction of tolerance. Our aim was to investigate the role of CD4+CD25+Foxp3+ T cells and IL-10-secreting type I T regulatory (Tr1) cells in the response to one year of cluster SIT to Dermatophagoides pteronyssinus for allergic rhinitis in children. CD4+CD25+Foxp3+regulatory T cells and IL-10-secreting type I T regulatory (Tr1) cells were analyzed in children allergic to Dermatophagoides pteronyssinus during one year cluster specific immunotherapy (SIT) in a prospective and randomized study. Peripheral blood mononuclear cells (PBMCs) were collected from 25 children receiving SIT and 21 receiving pharmacotherapy. The frequencies of CD4+CD25+Foxp3+ T cells and allergen-specific IL-10+IL-4-, IFN-γ+IL-4-, IL-4+IFN-γ-CD4+ T cells were measured by flow cytometry. Production of IL-4, IFN-r, and IL-10 in supernatants from allergen-stimulated PBMC culture was measured by ELISA. Finally, the suppressive effect of CD4+CD25highTreg cells from both groups was estimated.
NCT01702103 Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays Unknown status PH&T S.p.A. Phase 3 2012-10-01 Demonstrate the therapeutic clinical equivalence of two mometasone nasal sprays in the relief of the signs and symptoms of perennial allergic rhinitis, in term of changes at week 8 from baseline of Total Nasal Symptom Scores (TNSS).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS

Condition Name

Condition Name for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS
Intervention Trials
Allergic Rhinitis 4
Itching 1
Effects of Immunotherapy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS
Intervention Trials
Rhinitis, Allergic 4
Rhinitis 4
Nasal Obstruction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS

Trials by Country

Trials by Country for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS
Location Trials
Korea, Republic of 3
China 1
Argentina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS

Clinical Trial Phase

Clinical Trial Phase for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS
Clinical Trial Phase Trials
Phase 3 1
Phase 1 2
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS
Clinical Trial Phase Trials
Completed 2
Unknown status 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS

Sponsor Name

Sponsor Name for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS
Sponsor Trials
Gachon University Gil Medical Center 2
PH&T S.p.A. 1
Beijing Tongren Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for HOUSE DUST MITE, DERMATOPHAGOIDES PTERONYSSINUS
Sponsor Trials
Other 6
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Mallinckrodt
AstraZeneca
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.